Analysis of the Concordance Between the Use of Phenotypic Screening Tests with the β-Lactamase Gene Profile in Selected Gram-Negative Bacteria
Abstract
1. Introduction
2. Results
2.1. Growth on Chromogenic Media Brilliance™ CRE and Brilliance™ ESBL
2.2. Antimicrobial Susceptibility Assessment Using Phenotypic Methods
2.3. Molecular Analysis of the Occurrence of Resistance Genes
2.4. Correlation of the Occurrence of Resistance Genes with Antibiotic Resistance
2.5. PCA of Antimicrobial Resistance and Genotypic Profiles
3. Discussion
4. Materials and Methods
4.1. Bacterial Strains
4.1.1. Chromogenic Media
4.1.2. Antimicrobial Susceptibility Testing—Disc Diffusion Methodology
4.2. Molecular Methods RT-PCR Assay
4.3. Software and Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Skarżyńska, M.; Zając, M.; Wasyl, D. Antibiotics and bacteria: Mechanisms of action and resistance strategies. Adv. Microbiol. 2020, 59, 49–62. [Google Scholar] [CrossRef]
- Laudy, A.E.; Róg, P.; Smolińska-Król, K.; Ćmiel, M.; Słoczyńska, A.; Patzer, J.; Dzierżanowska, D.; Wolinowska, R.; Starościak, B.; Tyski, S. Prevalence of ESBL-producing Pseudomonas aeruginosa isolates in Warsaw, Poland, Detected by various phenotypic and genotypic methods. PLoS ONE 2017, 12, e0180121. [Google Scholar] [CrossRef]
- Sati, H.; Carrara, E.; Savoldi, A.; Hansen, P.; Garlasco, J.; Campagnaro, E.; Boccia, S.; Castillo-Polo, J.A.; Magrini, E.; Garcia-Vello, P.; et al. The WHO Bacterial Priority Pathogens List 2024: A Prioritisation Study to Guide Research, Development, and Public Health Strategies Against Antimicrobial Resistance. Lancet Infect. Dis. 2025, 25, 1033–1043. [Google Scholar] [CrossRef] [PubMed]
- Brzozowski, M.; Kwiatkowski, P.; Danuta Kosik-Bogacka, D.K.-B.; Jursa-Kulesza, J. The application of genotyping and phenotyping techniques for epidemiological analysis of microorganisms. Adv. Microbiol. 2017, 56, 353–366. [Google Scholar]
- Dzierżanowska-Fangrat, K.; Gniadkowski, M.; Hońdo, Ł.; Hryniewicz, W.; Literacka, E.; Mączyńska, A.; Ozorowski, T.; Papierowska-Kozdój, W.; Pawlik, K.; Wanke-Rytt, M.; et al. Carbapenemase—Producing Enterobacterales (CPE): Epidemiology, Diagnosis, Treatment, and Infection Prevention; Hryniewicz, W., Kuch, A., Wanke-Rytt, M., Żukowska, A., Eds.; National Medicines Institute: Warsaw, Poland, 2022. [Google Scholar]
- Perry, J.D. A decade of development of chromogenic culture media for clinical microbiology in an era of molecular diagnostics. Clin. Microbiol. Rev. 2017, 30, 449–479. [Google Scholar] [CrossRef]
- Anjum, M.F.; Zankari, E.; Hasman, H. Molecular methods for detection of antimicrobial resistance. Microbiol. Spectr. 2017, 5, 33–50. [Google Scholar] [CrossRef]
- Rasheed, J.K.; Tenover, F.C. Detection and characterization of antimicrobial resistance genes in pathogenic bacteria. In Manual of Clinical Microbiology; Wiley: Hoboken, NJ, USA, 2011; pp. 1239–1261. [Google Scholar] [CrossRef]
- Garsevanyan, S.; Barlow, M. The Klebsiella pneumoniae carbapenemase (KPC) β-lactamase has evolved in response to ceftazidime avibactam. Antibiotics 2023, 13, 40. [Google Scholar] [CrossRef]
- Viau, R.; Frank, K.M.; Jacobs, M.R.; Wilson, B.; Kaye, K.; Donskey, C.J.; Perez, F.; Endimiani, A.; Bonomo, R.A. Intestinal carriage of carbapenemase-producing organisms: Current status of surveillance methods. Clin. Microbiol. Rev. 2016, 29, 1–27. [Google Scholar] [CrossRef]
- Tamma, P.D.; Simner, P.J. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J. Clin. Microbiol. 2018, 56, 10–1128. [Google Scholar] [CrossRef]
- Grundmann, H.; Glasner, C.; Albiger, B.; Aanensen, D.M.; Tomlinson, C.T.; Andrasević, A.T.; Cantón, R.; Carmeli, Y.; Friedrich, A.W.; Giske, C.G.; et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE): A prospective, multinational study. Lancet Infect. Dis. 2017, 17, 153–163. [Google Scholar] [CrossRef]
- Rincón-Real, A.A.; Suárez-Alfonso, M.C. Carbapenem resistance in critically important human pathogens isolated from companion animals: A systematic literature review. Osong Public. Health Res. Perspect. 2022, 13, 407–423. [Google Scholar] [CrossRef]
- Hammoudi Halat, D.; Ayoub Moubareck, C. The current burden of carbapenemases: Review of significant properties and dissemination among gram-negative bacteria. Antibiotics 2020, 9, 186. [Google Scholar] [CrossRef] [PubMed]
- Husna, A.; Rahman, M.; Badruzzaman, A.T.M.; Sikder, M.H.; Islam, M.R.; Rahman, T.; Alam, J.; Ashour, H.M. Extended-Spectrum β-Lactamases (ESBL): Challenges and opportunities. Biomedicines 2023, 11, 2937. [Google Scholar] [CrossRef] [PubMed]
- Hall, B.G.; Barlow, M. Revised Ambler classification of β-lactamases. J. Antimicrob. Chemother. 2005, 55, 1050–1051. [Google Scholar] [CrossRef] [PubMed]
- Rossolini, G.M.; D’Andrea, M.M.; Mugnaioli, C. The spread of CTX-M-Type Extended-Spectrum β-Lactamases. Clin. Microbiol. Infect. 2008, 14, 33–41. [Google Scholar] [CrossRef]
- Gniewosz, M.; Andrzejczak-Grządko, S. Characterization of bacterial antimicrobial resistance, focusing on KPC-type resistance. Adv. Biochem. 2024, 70, 315–324. [Google Scholar] [CrossRef]
- Nong, L.; Jonker, M.; de Leeuw, W.; Wortel, M.T.; ter Kuile, B. Progression of AmpC amplification during de novo amoxicillin resistance development in E. coli. mBio 2025, 16, e0298224. [Google Scholar] [CrossRef]
- Bedenić, B.; Pospišil, M.; Nad, M.; Bandić Pavlović, D. Evolution of β-lactam antibiotic resistance in Proteus species: From extended-spectrum and plasmid-mediated AmpC β-lactamases to carbapenemases. Microorganisms 2025, 13, 508. [Google Scholar] [CrossRef]
- Romo-Ibáñez, Á.; Calatrava-Hernández, E.; Gutiérrez-Soto, B.; Pérez-Ruiz, M.; Navarro-Marí, J.M.; Gutiérrez-Fernández, J. High clinical impact of rapid susceptibility testing on CHROMID ESBL® medium directly from swabs. Ann. Transl. Med. 2020, 8, 604. [Google Scholar] [CrossRef]
- Huang, T.-D.; Bogaerts, P.; Berhin, C.; Guisset, A.; Glupczynski, Y. Evaluation of Brilliance ESBL Agar, a novel chromogenic medium for detection of extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J. Clin. Microbiol. 2010, 48, 2091–2096. [Google Scholar] [CrossRef]
- Elshenawy, A.; El-Bendary, S.; Mahmood, Y.; Mahmoud, F. Rapid detection of carbapenemases producing Enterobacteriaceae (CPE) by ChromaticTM CPE media in Intensive Care Units in Ain Shams University Hospitals. Microbes Infect. Dis. 2023, 4, 522–529. [Google Scholar] [CrossRef]
- Dikoumba, A.-C.; Onanga, R.; Jean-Pierre, H.; Didelot, M.-N.; Dumont, Y.; Ouedraogo, A.-S.; Ngoungou, E.-B.; Godreuil, S. Prevalence and phenotypic and molecular characterization of carbapenemase-producing gram-negative bacteria in Gabon. Am. J. Trop. Med. Hyg. 2023, 108, 268–274. [Google Scholar] [CrossRef] [PubMed]
- Manandhar, S.; Zellweger, R.M.; Maharjan, N.; Dongol, S.; Prajapati, K.G.; Thwaites, G.; Basnyat, B.; Dixit, S.M.; Baker, S.; Karkey, A. A high prevalence of multi-drug resistant gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-encoding Genes. Ann. Clin. Microbiol. Antimicrob. 2020, 19, 48. [Google Scholar] [CrossRef] [PubMed]
- Kazemian, H.; Heidari, H.; Ghanavati, R.; Ghafourian, S.; Yazdani, F.; Sadeghifard, N.; Valadbeigi, H.; Maleki, A.; Pakzad, I. Phenotypic and genotypic characterization of ESBL-, AmpC-, and carbapenemase-producing Klebsiella pneumoniae and Escherichia coli isolates. Med. Princ. Pract. 2019, 28, 547–551. [Google Scholar] [CrossRef]
- Baroud, M.; Dandache, I.; Araj, G.F.; Wakim, R.; Kanj, S.; Kanafani, Z.; Khairallah, M.; Sabra, A.; Shehab, M.; Dbaibo, G.; et al. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: Role of OXA-48 and NDM-1 carbapenemases. Int. J. Antimicrob. Agents 2013, 41, 75–79. [Google Scholar] [CrossRef]
- Ciftici, A.Y.; Karakece, E.; Atasoy, A.R.; Asik, G.; Ciftci, I.H. Culture media for detection of Acinetobacter baumannii selective media for detection of A. baumannii. J. Microbiol. Exp. 2015, 2, 1–4. [Google Scholar] [CrossRef]
- European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 15.0. 2025. Available online: http://www.eucast.org/clinical_breakpoints (accessed on 2 June 2025).









| K. pneumoniae N = 63 n (%) | A. baumannii N = 25 n (%) | E. coli N = 13 n (%) | |
|---|---|---|---|
| Carbapenemase | |||
| NDM | 29 (46.03) | 0 (0) | 5 (38.46) |
| OXA-48 | 12 (19.04) | 0 (0) | 0 (0) |
| VIM | 0 (0) | 0 (0) | 1 (7.70) |
| KPC | 22 (34.92) | 0 (0) | 1 (7.70) |
| OXA-24/40 | 0 (0) | 21 (84.00) | 0 (0) |
| OXA-51 | 0 (0) | 24 (96.00) | 0 (0) |
| OXA-23 | 0 (0) | 3 (12.00) | 0 (0) |
| ESBL | |||
| TEM | 26 (41.26) | 5 (20.00) | 6 (46.15) |
| SHV | 53 (84.12) | 0 (0) | 0 (0) |
| CTX-M-15 | 56 (88.89) | 0 (0) | 7 (53.85) |
| AmpC | |||
| CMY-2 | 0 (0) | 0 (0) | 4 (30.77) |
| DHA | 0 (0) | 0 (0) | 1 (7.70) |
| Name of the Microorganism | Klebsiella pneumoniae | Acinetobacter baumannii | Escherichia coli |
|---|---|---|---|
| body cavity fluid | 1 | 0 | 0 |
| blood | 18 | 13 | 7 |
| blood from puncture site | 1 | 0 | 0 |
| urine | 5 | 0 | 0 |
| rectum | 25 | 5 | 6 |
| pressure ulcer | 1 | 0 | 0 |
| leg ulcer | 0 | 1 | 0 |
| bronchoalveolar lavage fluid | 9 | 6 | 0 |
| wound | 3 | 0 | 0 |
| In total | 63 | 25 | 13 |
| Species | Antibiotic Classes and Agents (Abbreviation, µg) |
|---|---|
| Klebsiella pneumoniae | Penicillins: ampicillin (AMP, 10), piperacillin (PRL, 30), piperacillin/tazobactam (TZP, 36), amoxicillin/clavulanic acid (AMC, 20/10) |
| Cephalosporins: cefoxitin (FOX, 30), cefotaxime (CTX, 5), ceftazidime (CAZ, 10), cefepime (FEP, 30) | |
| Carbapenems: imipenem (IPM, 10), Meropenem (MEM, 10), ertapenem (ETP, 10) | |
| Aminoglycosides: gentamicin (CN, 10), amikacin (AK, 30) | |
| Fluoroquinolones: ciprofloxacin (CIP, 5), levofloxacin (LEV, 5) | |
| Other: trimethoprim/sulfamethoxazole (SXT, 25), Temocillin (TEM, 30) | |
| Acinetobacter baumannii | Carbapenems: imipenem (IPM, 10), meropenem (MEM, 10) |
| Aminoglycosides: gentamicin (CN, 10), amikacin (AK, 30) | |
| Fluoroquinolones: ciprofloxacin (CIP, 5), levofloxacin (LEV, 5) | |
| Other: trimethoprim/Sulfamethoxazole (SXT, 25) | |
| Escherichia coli | Penicillins: ampicillin (AMP, 10), piperacillin (PRL, 30), piperacillin/tazobactam (TZP, 36), Amoxicillin/Clavulanic acid (AMC, 20/10) |
| Cephalosporins: cefoxitin (FOX, 30), cefotaxime (CTX, 5), ceftazidime (CAZ, 10), cefepime (FEP, 30) | |
| Carbapenems: imipenem (IPM, 10), meropenem (MEM, 10), ertapenem (ETP, 10) | |
| Aminoglycosides: gentamicin (CN, 10), amikacin (AK, 30) | |
| Fluoroquinolones: ciprofloxacin (CIP, 5), levofloxacin (LEV, 5) | |
| Other: trimethoprim/sulfamethoxazole (SXT, 25), temocillin (TEM, 30), nitrofurantoin (F, 100) |
| Test Name Streck ARM-D Kit | Genes Detected in the Test |
|---|---|
| Streck ARM-D Kit β-Laktamase | IMP-1, NDM, OXA-48, CMY-2, CTX-M-14, CTX-M-15, DHA, VIM, KPC |
| Streck ARM-D Kit OXA | OXA-143, OXA-48, OXA-24/40, OXA-58, OXA-51, OXA-23 |
| Streck ARM-D Kit TEM/SHV/GES | TEM, SHV, GES |
| Streck ARM-D Kit ampC | DHA, CMY-2 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Głowacka, P.; Marczuk, I.; Wójcicka, P.; Ogórkiewicz, M.; Ciesielska, M.; Żakowska, D.; Rutyna, P.; Koszczyńska, A.; Łączyńska, M.; Podsiadły, N.; et al. Analysis of the Concordance Between the Use of Phenotypic Screening Tests with the β-Lactamase Gene Profile in Selected Gram-Negative Bacteria. Antibiotics 2025, 14, 1275. https://doi.org/10.3390/antibiotics14121275
Głowacka P, Marczuk I, Wójcicka P, Ogórkiewicz M, Ciesielska M, Żakowska D, Rutyna P, Koszczyńska A, Łączyńska M, Podsiadły N, et al. Analysis of the Concordance Between the Use of Phenotypic Screening Tests with the β-Lactamase Gene Profile in Selected Gram-Negative Bacteria. Antibiotics. 2025; 14(12):1275. https://doi.org/10.3390/antibiotics14121275
Chicago/Turabian StyleGłowacka, Patrycja, Izabela Marczuk, Patrycja Wójcicka, Monika Ogórkiewicz, Marta Ciesielska, Dorota Żakowska, Paweł Rutyna, Anna Koszczyńska, Marta Łączyńska, Natalia Podsiadły, and et al. 2025. "Analysis of the Concordance Between the Use of Phenotypic Screening Tests with the β-Lactamase Gene Profile in Selected Gram-Negative Bacteria" Antibiotics 14, no. 12: 1275. https://doi.org/10.3390/antibiotics14121275
APA StyleGłowacka, P., Marczuk, I., Wójcicka, P., Ogórkiewicz, M., Ciesielska, M., Żakowska, D., Rutyna, P., Koszczyńska, A., Łączyńska, M., Podsiadły, N., Paziewska, E., & Cieśluk-Olchowska, B. (2025). Analysis of the Concordance Between the Use of Phenotypic Screening Tests with the β-Lactamase Gene Profile in Selected Gram-Negative Bacteria. Antibiotics, 14(12), 1275. https://doi.org/10.3390/antibiotics14121275

